| Authors: |
Azad AA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Agarwal N; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Armstrong AJ; Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, USA., Hellmis E; Urologicum Duisburg, Center for Urology and Urologic Cancer, Duisburg, Germany., Sugimoto M; Department of Urology, Kagawa University, Kagawa, Japan., Ürün Y; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey., Xing N; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Aregay M; Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Lima J; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Meulendijks D; Global Medicines Development, Oncology R&D, AstraZeneca, Barcelona, Spain., Chi KN; Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada. |
